Tobacco smoking, nicotine, and nicotine and non-nicotine replacement therapies

Heart Disease

Volumn 3, Issue 6, 2001, Pages 365-377

  Frishman, W H ^a   Ky, T ^a   Ismail, A ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cigarette smoking; Nicotine; Nicotine withdrawal; Smoking withdrawal; Tobacco smoking

Indexed keywords

ALCOHOL DERIVATIVE; ALDEHYDE; AMFEBUTAMONE; AMMONIA; CARBON DIOXIDE; CARBON MONOXIDE; CLONIDINE; COCAINE; HYDROCARBON; KETONE; LOBELINE; METAL ION; NICOTINE; NICOTINE GUM; NITRIC OXIDE; NITRITE; NITROGEN DERIVATIVE; NITROGEN OXIDE; NITROSAMINE; NORTRIPTYLINE; PLASMINOGEN ACTIVATOR INHIBITOR; POLONIUM; POLYCYCLIC AROMATIC HYDROCARBON; SILVER DERIVATIVE; SULFUR DERIVATIVE; TAR; TOBACCO SMOKE; UNINDEXED DRUG;

ADDICTION; BLOOD CLOTTING; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COUGHING; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HICCUP; HUMAN; INSOMNIA; REVIEW; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; THROMBOGENESIS; TOBACCO; VERTIGO; XEROSTOMIA;

EID: 0035658425     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200111000-00005     Document Type: Review

References (158)

1. Basic and clinical psychopharmacology of nicotine
2. The health benefits of smoking cessation
3. The health consequences of smoking: Cardiovascular disease
4. Smoking and death rates. Report on forty-four months of follow up of 187,783 men. I. Total mortality
5. Smoking and death rates. Report on forty-four months of follow up of 187,783 men. II. Death rates by cause
6. Smoking increases tissue factor expression in atherosclerotic plaques. Implications for plaque thrombogenicity
7. Nicotine is a potent blocker of the cardiac A-type K+ channels. Effects on cloned Kv4.3 channels and native transient outward current
8. Effect of cigar smoking on the risk of cardiovascular disease. Chronic obstructive pulmonary disease and cancer in men
9. Cigar smoking and death from coronary heart disease in a prospective study of US men
10. Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol. The Korea Medical Insurance Corporation Study
11. Cigarette smoking and hemostatic function
12. Acute effects of cigarette smoking on platelet-dependent thrombin generation
13. Effect of smoking on lipid and thrombogenic factors two months after acute myocardial infarction
14. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking. A mechanism for arterial thrombosis and myocardial infarction
15. Cigarette smoking increases sympathetic outflow in humans
16. Some long-term effects of smoking on the hemostatic system: A report from Caerphilly and Speedwell Collaborative Surveys
17. Effect of smoking on blood coagulation and platelet survival in man
18. Acute platelet activation induced by smoking
19. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin
20. Impaired fibrinolysis in cigarette smokers in the Framingham Offspring Study
21. Mechanisms of cigarette smoke induced impairment of endothelium dependent modulation of vascular tone [abstract]
22. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function
23. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease
24. Hemodynamic and vascular effects of active and passive smoking
25. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: Role of oxidized LDL
26. Acute effects of cigarette smoking on coronary circulation: Constriction of epicardial and resistance vessels
27. Cocaine-induced coronary artery disease: Recognition and treatment
28. Cardiovascular complications of cocaine use
29. Impaired action of thyroid hormone associated with smoking in women with hypothyroidism
30. Cigarette smoking and the treatment of angina with propranolol, atenolol and nifedipine
31. Cigarette smoking is a major risk factor for coronary spasm
32. Increased frequency of restenosis in patients continuing to smoke cigarettes after percutaneous transluminal coronary angioplasty
33. Smoking and cardiac events after venous coronary bypass surgery: A I year follow-up study
34. A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians
35. Life expectancy following dietary modification or smoking cessation: Estimating the benefits of a prudent lifestyle
36. The impact of smoking and quitting on health care use
37. Association of the California tobacco control program with declines in cigarette consumption and mortality from heart disease
38. The tobacco use and dependence clinical practice guidelines panel, staff, and consortium representatives. A clinical practice guideline for treating tobacco use and dependence. A US Public Health Service Report
39. Effect of smoking cessation on mortality after myocardial infarction
40. Cigarette smoking and mortality risk. Twenty-five-year follow-up of the Seven Countries Study
41. Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine
42. Oxidative metabolism of nicotine in vivo
43. Metabolism of nicotine by the isolated perfused dog lung
44. Metabolism of nicotine by human liver microsomes stereoselective formation of trans-nicotine N9-oxide
45. Cigarette smoking: A dependence on high nicotine boli
46. Metabolism pharmacokinetics and pharmacodynamics in man
47. Relationship between intcrindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans
48. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers
49. Nicotine metabolism in nonsmokers [letter]
50. Cotinine deposition and effects
51. Kinetics of cotinine after oral and intravenous administration to man
52. Pharmacological aspects of cigarette smoking and nicotine addiction
53. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors
54. Hemodynamic and regional blood flow responses to nicotine at rest and during exercise
55. Neuroregulators and the reinforcement of smoking: Towards a biobehavioral explanation
56. A scale to differentiate between types of smoking as related to the management of affect
57. Smoking motivation factors
58. A situation specific model for smoking behavior
59. Smoking behaviour and its relation to the smokers immediate experience
60. Pharmacological and nonpharmacological smoking motives: A replication and extension
61. The classification of smoking by factorial structure of motives
62. Higher levels of nicotine in arterial than venous blood after cigarette smoking
63. Clinical pharmacology of inhaled drugs of abuse: Implications in understanding nicotine dependence
64. Nicotine replacement therapy: What has been accomplished. Can we do better?
65. Establishing nicotine threshold for addiction: The implications for tobacco regulation
66. The influence of smoking cessation on the prevalence of overweight in the United States
67. Anti-smoking therapies: Is harm reduction a viable alternative to smoking cessation?
68. Stable isotope studies of nicotine kinetics and bioavailability
69. The power to regulate tobacco
70. Acute effects of passive smoking on the coronary circulation in healthy young adults
71. Even a little secondhand smoke is dangerous
72. Environmental tobacco smoke promotes heart disease
73. The effects of short-term passive smoke exposure on endothelium-dependent and independent vasodilation
74. Effects of L-arginine on atherogenesis and endothelial dysfunction due to secondhand smoke
75. Passive smoking and the risk of coronary heart disease: A recta-analysis of epidemiologic studies
76. Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults
77. Even a little secondhand smoke is dangerous
78. Passive smoking in children: Radal differences in systemic exposure to cotinine by hair and urine analysis
79. Pharmacogenetics and ethnoracial differences in smoking
80. Centers for disease control and prevention cigarette smoking among adults. U.S. 1991
81. Pharmacodynamics of nicotine: Implication rational treatment of nicotine addiction
82. Nicotine medications for smoking cessation
83. An analysis of the effectiveness of interventions intended to help people stop smoking
84. Nicotine replacement for smokers
85. Nicotine and coronary heart disease
86. Nicotine replacement therapy during pregnancy
87. Working group for the study of transdermal nicotine in patients with coronary artery disease. Nicotine replacement therapy for patients with coronary artery disease
88. Risk of acute myocardial infarction and use of nicotine patches in a general population
89. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler
90. Recent advances in the pharmacotherapy of smoking
91. Treatment of nicotince dependence
92. An alternative approach to smoking control
93. A pilot study of smokeless tobacco in smoking cessation
94. Controlled trial of transdermal nicotine patch in tobacco withdrawal
95. Transdermal nicotine for smoking cessation
96. A double-blind trial of 16 hour transdermal nicotine patch in smoking cessation
97. Analysis of the effectiveness of interventions intended to help people stop smoking
98. Cost-effectiveness of the transdermal nicotine patch as mi adjunct to physicians smoking cessation counseling
99. Determinants of nicotine intake while chewing nicotine polacrilex gum
100. Comparison of plasma nicotine concentrations for nicotine transdermal system (NTS), cigarette smoking and nicotine polacrilex (nicotine gum)
101. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation
102. Varying nicotine patch dose and type of smoking cessation counseling
103. Treatment of nicotine dependence. Is more better?
104. Stable isotope method for studying transdermal drug absorption: The nicotine patch
105. Tobacco use and cessation
106. Nicotine effects on cicosamoid formation and hemostaric function: Comparison of transdermal nicotine and cigarette smoking
107. Effectiveness of the 4 mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers
108. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum
109. Safety of nicotine polacrilex gum used by 3,094 participants in the lung health study
110. Plasma nicotine concentrations from repeated doses of nasal nicotine solution
111. Clinical pharmacokinetics of nasal nicotine delivery: A review and comparison to other nicotine systems
112. Dependence on and abuse of nicotine replace: An update
113. Nicotine nasal spray and vapor inhaler: Abuse liability assessment
114. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation. A randomized, doubleblind, placebo-controlled trial
115. Smoking reduction with oral nicotine inhalers: Double blind, randomised clinical trial of efficacy and safety
116. Nicotine nasal spray with nicotine patch for smoking cessation: Randomised trial with six year follow up
117. Temperature dependency of the release and bioavailability of nicotine from nicotine vapour inhaler: In vitro/in vivo correlation
118. Bopropion: A review of its mechanism of antidepressant activity
119. Bupropion: A review of its use in the management of smoking cessation
120. A comparison of sustained release bupropion and placebo for smoking cessation
121. Effectiveness of Bupropion for smoking cessation in smokers with a former history of major depression or alcoholism
122. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo-controlled study
123. Sustained release bupropion for pharmacologic relapse prevention after smoking cessation
124. A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation
125. New developments in smoking cessation
126. Tobacco use and cessation: Non-nicotine pharmacotherapy for smoking cessation
127. Heavy smokers, smoking cessation, and clonidine: Results of a double-blind randomized trial
128. A recta-analysis of double-blind placebo controlled trials of clonidine for smoking cessation
129. Nortriptyline and cognitive-behavioral, therapy in the treatment of cigarette smoking
130. Treatment: Nortriptyline was associated with an increased rate of 6 month smoking cessation
131. Drug may suppress the craving for nicotine
132. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers
133. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease
134. Tobacco, the food and drug administration, and congress
135. Beyond the tobacco settlement [editorial]
136. The master settlement agreement with the tobacco industry and cigarette advertising in magazines
137. OTC nicorette data summary
138. Nicotine gum in smoking cessation
139. Over-the-counter (OTC) transdermal nicotine patch therapy
140. Nicoderm Data Summary
141. The efficacy of nicotine patch as an over-the-counter medication
142. Nicotrol Data Summary
143. Nicotine patches in smoking cessation
144. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation
145. Effect of nicotine nasal spray on smoking cessation
146. Efficacy of a nicotine nasal spray in smoking cessation: A placebo-controlled, double-blind trial
147. Randomised controlled trial of nasal nicotine spray in smoking cessation
148. Efficacy of the nicotine inhaler as an adjunct to smoking cessation
149. Routine smoking cessation with 4 nicotine regimens in a lung clinic
150. Efficacy of a nicotine inhaler in smoking cessation: A double-blind, placebo-controlled trial
151. A double-blind trial of a nicotine inhaler for smoking cessation
152. Efficacy of bupropion for smoking cessation in nondepressed smokers
153. A comparison of sustained-release bupropion and placebo for smoking cessation